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ABSTRACT
Objective: Artificial intelligence (AI) offers new opportunities for objective quantitative measurements
of imaging biomarkers from positron-emission tomography/computed tomography (PET/CT). Clinical
image reporting relies predominantly on observer-dependent visual assessment and easily accessible
measures like SUVmax, representing lesion uptake in a relatively small amount of tissue. Our hypothesis
is that measurements of total volume and lesion uptake of the entire tumour would better reflect the
diseases activity with prognostic significance, compared with conventional measurements.
Methods: An AI-based algorithm was trained to automatically measure the prostate and its tumour
content in PET/CT of 145 patients. The algorithm was then tested retrospectively on 285 high-risk
patients, who were examined using 18F-choline PET/CT for primary staging between April 2008 and
July 2015. Prostate tumour volume, tumour fraction of the prostate gland, lesion uptake of the entire
tumour, and SUVmax were obtained automatically. Associations between these measurements, age,
PSA, Gleason score and prostate cancer-specific survival were studied, using a Cox proportional-haz-
ards regression model.
Results: Twenty-three patients died of prostate cancer during follow-up (median survival 3.8 years).
Total tumour volume of the prostate (p¼ 0.008), tumour fraction of the gland (p¼ 0.005), total lesion
uptake of the prostate (p¼ 0.02), and age (p¼ 0.01) were significantly associated with disease-specific
survival, whereas SUVmax (p¼ 0.2), PSA (p¼ 0.2), and Gleason score (p¼ 0.8) were not.
Conclusion: AI-based assessments of total tumour volume and lesion uptake were significantly associ-
ated with disease-specific survival in this patient cohort, whereas SUVmax and Gleason scores were not.
The AI-based approach appears well-suited for clinically relevant patient stratification and monitoring
of individual therapy.
Abbreviations: BSI: bone scan index; CNN: convolutional neural network; PET: positron emission tom-
ography; CT: computed tomography; PSA: prostate specific antigen; SDI: Sørensen-Dice index; SUV:
standardized uptake value.
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Positron emission tomography/computed tomography (PET/
CT) is increasingly being used in several types of malignan-
cies, including prostate cancer [1–4]. PET/CT has been pro-
posed as the sole imaging modality for primary lymph node
and bone staging of prostate cancer based on higher sensi-
tivity and specificity compared to conventional imaging tech-
niques [5]. Detection of intraprostatic tumour localisation
with PET/CT to guide targeted biopsy has also been sug-
gested [6].
However, the analysis and clinical reports for PET/CT still
rely predominantly on visual assessment and semi-auto-
mated measurements; probably due to the fact that proper
quantification of disease processes is time-consuming and
mainly based on manual procedures. Visual assessment is
associated with inter-observer variability both in clinical
reporting and research. Further, the most easily obtained
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measurement available is the maximum standardised uptake
value (SUVmax). The prognostic significance of the sum of
SUVmax in patients with prostate cancer was presented sev-
eral years ago [7], though the clinical value of this measure-
ment has been shown to be relatively limited, especially
when it comes to evaluation of tumour response [8,9]. One
reason for this could be that SUVmax may be biased by dis-
proportionate uptake in a relatively small amount of tissue,
and may not correlate to total disease burden.
Meanwhile, artificial intelligence (AI) offers new opportuni-
ties to analyse scans and provide objective, observer-inde-
pendent measurements of tumour detection, segmentation
and classification in a range of malignancies [10–12]. The
bone scan index (BSI) is an AI-based two-dimensional
approach used to quantify skeletal metastasis in bone scan
scintigraphy, which has recently been validated and
approved for clinical use [13,14]. It provides important prog-
nostic information, not contained in the visual reports. AI-
based three-dimensional methods applied to whole-body
PET/CT could most likely have an even greater clinical impact
[15].
A recent study developed an AI-based method for auto-
mated analysis of the prostate in PET/CT. The resulting meas-
urements of lesion uptake in the tumour were associated
with overall survival in a group of patients with high-risk
prostate cancer and known bone metastases [14,15]. In the
current study, we take this approach one step further by
applying an improved AI-based method to a group of high-
risk prostate cancer patients considered for curative treat-
ment at the time of staging and using disease-specific rather
than overall survival as the endpoint.
Thus, the aim of this retrospective study was to investi-
gate the association between AI-derived measurements of
tumour volume and lesion uptake and disease-specific sur-
vival, compared to the prognostic value of other clinical data




The AI-algorithm was trained and validated using 143 PET/CT
scans from a recent study [16]. The characteristics of the
patient groups have been described in detail else-
where [16,17].
The algorithm was then applied to a separate test set of
304 prostate cancer patients, who were examined using 18F-
choline PET/CT for primary staging (Table 1). The PET/CT
examinations in this set were performed at another institu-
tion and with different cameras than the training/validation
set in [16]. The patients had been part of previous studies
with the following inclusion criteria: newly diagnosed high-
risk prostate cancer patients (defined as PSA above 20 ng/ml,
and/or clinical tumour stage T3, and/or Gleason score 8–10)
with normal or inconclusive bone scintigraphy [18,19]. The
exclusion criteria were hormonal therapy before PET/CT, or
PSA 150 ng/ml. The PET/CT examinations were performed
between April 2008 and July 2015, the results of which were
not part of the exclusion criteria. Clinical information was col-
lected from the local medical records up to April 2019. The
treatment for each patient was selected by the treating
urologist in consultation with the patient. In general, patients
with no evidence of metastatic disease received curative
treatment (radical prostatectomy or radiation therapy), while
patients that had metastatic disease received palliative treat-
ment (androgen deprivation therapy) based on the PET/CT
findings. The clinical characteristics of the 285 patients are
shown in Table 1.
These retrospective studies were approved by the
Research Ethical Review Board at the University of Lund (EPN
LU 552/2007 and 2016/61) and the Regional Ethics Review




Training and validation data were obtained using two differ-
ent PET/CT scanners and protocols: an integrated PET/CT
camera (Siemens Biograph 64 Truepoint), with a low dose CT
scan (64-slice helical, 120 kV, 30 mAs, and CT slice thickness
5mm) and a PET/CT scan (Discovery VCT, GE Healthcare),
with a contrast-enhanced CT scan (64-slice helical, 120 kV,
‘smart mA’ maximum 400mA, and CT slice thickness
3.75mm), approximately 60min after administration of 4
MBq/kg of 18F-choline. Both PET/CT scans were obtained
from the base of the skull to mid-thigh [16].
Test set
PET/CT scans were acquired by means of an integrated PET/
CT system (Philips Gemini TF, Philips Medical Systems,
Cleveland, OH, USA) at the Centre for Medical Imaging and
Physiology, Skåne University Hospital in Lund or
Malm€o [18,19].
Patients fasted for 4 h before 18F-choline injection. Whole-
body PET was acquired 1–1.5 h after intravenous injection of
4 MBq/kg (max. dose 400 MBq) of 18F-fluorocholine with
2min per bed position. A diagnostic quality CT scan was per-
formed immediately prior to the PET scan with 1000ml oral
contrast given 60min before the scan, and intravenous con-
trast (Omnipaque 350mg I/mL) given by an automatic injec-
tion pump with an injection speed of 2.5mL/s. A
multidetector spiral CT scanner was used, with 5mm recon-
structed slice thickness, rotation speed 0.75 s, 120 kV and
with high-beam tube current modulation (120–300mA)
based on the patient’s total body mass.
Image processing and interpretation
AI-model
The model from a recent study [20] was used to automatic-
ally segment the prostate gland. This model uses both the
PET image and the CT image to get an accurate segmenta-
tion and position of the prostate gland even when there is
misalignment between the PET and the CT image.
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Imaging biomarkers
The standardised uptake value (SUV) of PET images was
automatically calculated for the whole prostate volume. Each
voxel in the region classified as prostate with an SUV above
2.65 was considered abnormal [21]. The AI included voxels of
all the prostate lesions that could represent multifocal dis-
ease, even if these lesions were located separately from each
other. In order to remove uptake leaking from surrounding
tissue, Meyer’s flooding algorithm was used. This assigns
each high abnormal voxel to a local maximum in the PET
image. If this local maximum lies outside the region seg-
mented as the prostate, we assume that the abnormal voxel
is actually due to leakage, and we change the classification
to normal.
Automated measures were obtained for the total volume
of the gland in ml, maximum SUV within the prostate
(SUVmax), mean SUV of voxels considered abnormal (SUVmean)
and volume of abnormal voxels in ml (lesion VOLUME). To
reflect total lesion uptake (TLU), the product SUVmean 
VOLUME was calculated. Finally, the quotient of VOLUME
related to the total volume of the prostate gland was
defined as FRACTION.
Statistical analysis
Associations between automated PET/CT measurements, age,
PSA, Gleason score and disease-specific survival were investi-
gated using a univariate Cox proportional hazards regression
model. Disease-specific survival was calculated from the date
of PET/CT scan to the date of prostate cancer death or last
follow-up. Hazard ratios (adjusted for type of treatment: cura-
tive or palliative) and 95% confidence intervals (CI) were esti-
mated (bivariable analysis). Univariate analysis for patients
with metastatic disease (defined as N1and/or M1) was also
performed. Hazard ratio accounts for one unit change of
each of the automated PET variables, based on a median fol-
low-up of five years. The level of significance was set at 0.05.
The patients for the Kaplan-Meier analysis were grouped
according to the median value of the variable of interest.
The patients were divided into two different groups based
on their Gleason score (Gleason  7 and Gleason > 7). SPSS
version 25 (IBM, Armonk, NY, USA) was used for statis-
tical analysis.
Results
Patient group and death rate
The algorithm failed to perform automated measurements in
14 (5%) patients due to artefacts, caused by either hip pros-
thesis, peroral contrast in the bowel or tracer radioactivity in
the urinary bladder. Five patients were excluded due to miss-
ing follow-up (Figure 1). Of the remaining 285 prostate can-
cer patients, 219 (77%) received curative treatment.
Five patients were considered censored (death of other
causes) before the first prostate cancer death, making no
contribution to the estimation and are thus not used.
Out of a total of 285 patients, 23 died of prostate cancer
(8%) with a median survival time of 3.8 years (IQR 2.8–4.8)
during a median follow-up of five years (IQR 4.4–5.7). Of
these 23 patients, 18 (78%) received palliative treatment.
Disease-specific survival in association with
imaging biomarkers
The univariate Cox analysis showed that three of the volu-
metric measurements (lesion VOLUME, TLU and FRACTION)
made automatically by the AI-based algorithm, as well as
age, were significantly associated with disease-specific sur-
vival in contrast to the other PET/CT measurements (SUVmax
and SUVmean), PSA (logarithmic) and Gleason score for
patients receiving palliative treatment as well as for all
patients after adjusting for treatment. Further, the univariate
analysis showed that patients with metastatic disease had
worse survival than those with local cancer, even if they
Table 1. Clinical characteristics of patients in the test set (n¼ 285).
All patients (n¼ 285) Palliative treatment (n¼ 66) Curative treatment (n¼ 219)
Age, yrs
Median, (IQR)a 69 (65–72) 70 (67 73) 68 (64 72)
Gleason scale, No (%)
 6 11 (4%) 1 (2%) 10 (5%)
3þ 4 45 (16%) 5 (8%) 40 (18%)
4þ 3 38 (13%) 7 (11%) 31 (14%)
8 69 (24%) 16 (24%) 53 (24%)
9–10 122 (43%) 37 (56%) 85 (39%)
PSA, ng/ml
Median, (IQR)a 21 (10–36) 29 (13–56) 19 (9–32)
T-stage, No (%)
T1 49 (17%) 6 (9%) 43 (20%)
T2 104 (36%) 16 (24%) 88 (40%)
T3 129 (45%) 41 (62%) 88 (40%)
T4 3 (1%) 3 (5%) 0 (0%)
N1-stage, No (%) 41 (14%) 29 (44%) 12 (5%)
M-stage, No (%)
M1a 11 (4%) 11 (17%) 0 (0%)
M1b 10 (3%) 9 (14%) 1 (0.5%)
Follow-up time, yrs
Median, (IQR)a 5 (4.4–5.7) 4.5 (3.5–6) 5 (4.6–5.7)
Number of prostate cancer deaths, No (%) 23 (8%) 18 (27%) 5 (2%)
a Interquartile range.
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receive curative treatment (Table 2). The Kaplan-Meier sur-
vival was similar for patients with a Gleason score above and
below 7. Patients with a log-PSA value above the median
(3.04) tended towards worse survival during the whole fol-
low-up time, which did not reach statistical significance
(p¼ 0.07). The survival curves of patients with SUVmax above
and below the median crossed each other and after 6 years
of follow-up, there was a tendency towards worse survival
for patients with SUVmax above the median value (6.5).
Finally, the Kaplan-Meier survival was significantly worse for
patients with lesion VOLUME above the median value
(18.1mL, p< 0.001, Figure 2).
Discussion
The AI-based image analysis was able to accurately identify
the prostate in 95% of the PET/CT scans and the automated
quantification of total prostate tumour burden in these
patients was significantly associated with disease-specific sur-
vival for those who received non-curative treatment.
Although not specifically studied, it is possible that this could
be used as an objective marker for selecting which patients
with metastatic disease should receive more inten-
sive treatment.
The lesion volume, the tumour fraction of the prostate
volume, and the total lesion uptake, based on the AI algo-
rithm resulting in a 3D-based image analysis, seem to reflect
the total tumour infiltration of the gland. The volume-based
measurements were better prognosticators than SUVmax,
probably because they provide more information about the
total tumour than only a small number of cancer cells.
Similar results in relation to progression-free survival have
been demonstrated in the manual analysis of 11C-choline
PET/MRI [22].
The application of an AI algorithm to the prostate and its
association with overall survival with a high level of reliability
compared to experienced radiologists (Dice-Sørensen
coefficient 0.78–0.79) has previously been shown [16]. This AI
method has been further developed as described in a recent
study, which showed a significant correlation between the
automated volumetric measurements of the prostate and the
manual segmentations as well as the gland’s weight from
the histopathological specimens [20]. In the present study,
the improved version of the algorithm was used and the
number of patients was increased compared to the results
from Polymeri et al. [16]. At the same time, the test set con-
sisted of a large number of patients from another institution
that used a different PET/CT camera, increasing the accuracy
and generalisability of the algorithm. Further, disease-specific
rather than overall survival was used as the endpoint, while
bivariable analysis was performed after adjusting for treat-
ment. A prospective study with prostate-specific radiotracers
comparing the automated measurements with the histo-
pathological results or other known prognostic factors could
be considered in the future.
Other volume-based clinical measures, such as staging by
transrectal ultrasound (TRUS), have been shown to be
important tools for cancer staging and prognosis [23].
However, the heterogeneity of cancer itself [24] makes the
volumetric lesion analysis in TRUS suboptimal and examiner-
dependent. The Gleason Score for the tumour is another
known prognostic factor, however, the grading is highly sub-
jective and its reproducibility is not always perfect [25,26],
with the biopsies only sampling a small part of the tumour.
In contrast, the automated analysis of a PET/CT scan provides
information about the whole tumour and may offer a more
consistent result. Moreover, other well-known pre-treatment
risk stratification tools for prostate cancer have been ana-
lysed and compared in a recent study, showing that they
can contribute to treatment decision making in different
ways [27]. Analysis of imaging PET/CT measurements reflect-
ing the tumour infiltration of the prostate could be a com-
patible tool in establishing new prognostic variables. Other
prospective studies are needed in the future in order to ana-
lyse PET/CT variables in combination with other known prog-
nostic factors.
The main strength of the present study is the large pro-
portion of scans that were successfully analysed by the AI
algorithm, including patients with unilateral hip prostheses.
Further training of the algorithm on a group of patients with
anatomical variations in the pelvic region could, thus, poten-
tially improve its performance. Moreover, the potential future
use of metal artefacts’ reduction algorithms could further
improve the segmentation and quantification process by AI-
based algorithms.
Limitations
The most important limitations of the study are the relatively
short follow-up time, with few terminal events, and the use
of historical PET/CT scans, which were part of the staging
workup and thus influenced the treatment selection. The
local lesion uptake in the prostate was not, however, consid-
ered at the time of treatment, as the original aim of the PET/
CT scans was to detect metastasis. In addition, the patients
Figure 1. Study selection process. The Standards for Reporting Studies of
Diagnostic Accuracy (STARD) flow chart.
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in the test group were examined by 18F-choline-PET, due to
the availability of the scans at the time of this retrospective
study. Other prostate cancer-specific tracers have been
increasingly used in the last few years with a significant
improvement in sensitivity and specificity, if compared with
Choline-based tracers, such as prostate-specific membrane
antigen radiopharmaceuticals [3,28,29], which are being pre-
ferred. However, even with the use of radiolabeled choline in
the present study, the AI algorithm showed promising
results. Further, the long-time use of this tracer in several
medical centres gives the advantage of conducting studies
with longer follow-up. To the best of our knowledge, the
prognostic value of AI-derived volumetric prostate tumour
measurements in PET/CT is still undefined. The use of more
prostate cancer-specific tracers in future studies may thus
further improve the prognostic significance and clinical value
of the algorithm.
Moreover, the patient cohort for the present study con-
sisted of a rather heterogeneous group of individuals with
different T-stages and different treatments. By definition,
these factors alone could be important for prognosis,
although that was not found here which is likely due to all
the patients included having high-risk cancer [27]. Further,
the selection of patients with high PSA values and tumour
staging limits the generalisability of our study to patients
with advanced prostate cancer disease. Moreover, the small
number of prostate cancer-specific events during the follow-
up period prevented us from performing multivariate
Table 2. Associations between disease-specific survival and AI-based PET/CT measurements of biomarkers, as well as clinical data using univariate proportional
regression analysis.
Variables
Adjusted for treatment (n¼ 285) Palliative treatment (n¼ 66) Curative treatment (n¼ 219)
HR b (95% CI§) p HR b (95% CI§) † p HR b (95% CI§) † p
VOLUME a 1.03 (1.01–1.05) 0.008 1.03 (1.01–1.06) 0.008 1.01 (0.9–1.08) 0.7
TLU b 1.6 (1.08–2.4) 0.02 1.7 (1.06–2.7) 0.03 1.3 (0.56 3.2) 0.5
Fraction (%) c 1.03 (1.01–1.06) 0.005 1.04 (1.01–1.07) 0.007 1.02 (0.9–1.07) 0.4
Prostate SUVmax
d 1.1 (0.9–1.3) 0.2 1.1 (0.9–1.3) 0.3 1.1 (0.8–1.4) 0.5
Lesion SUVmean
e 1.4 (0.7–2.7) 0.3 1.4 (0.7–3.0) 0.4 1.3 (0.4–4.3) 0.6
Clinical data
Age 0.9 (0.8–0.98) 0.01 0.9 (0.8–0.95) 0.005 1.0 (0.8–1.09) 0.5
PSA (log) h 1.4 (0.8–2.3) 0.2 1.5 (0.8–2.7) 0.2 1.0 (0.4–2.7) 0.9
Gleason score i 1.2 (0.4–3.0) 0.8 1.2 (0.4–3.9) 0.7 0.8 (0.1–5.1) 0.8
Metastatic disease‡ 2.2 (0.8–5.8) 0.1 1.6 (0.5–4.5) 0.4 10.4 (1.7–63) 0.01
a Volume of prostate gland voxels with Standardized Uptake Value (SUV) >2.65; b Product of SUVmean  VOLUME reflecting the Total Lesion Uptake (TLU);.
c Fraction of lesion VOLUME related to the total volume of the prostate gland; d Maximum SUV within the prostate; e Average SUV of voxels with SUV >2.65;.
h Prostate-specific antigen (logarithmic); i Patients with Gleason >7 and reference Gleason 7; * Hazard ratio b; § 95% Confidence Interval; † Univariate analysis
stratified for treatment; ‡ Defined as N1 or M1.
Figure 2. Kaplan-Meier survival plots of the patients in the test group. The figure compares the survival curves between Gleason score, prostate SUVmax, PSA and
lesion VOLUME (n¼ 285). The upper curves of each graph represent the proportion of patients with values equal or below the median level of the variable of inter-
est (or Gleason  7 respectively), whereas the lower curves represent the proportion of patients with values above the median level of the variable of interest (or
Gleason > 7 respectively). p-value was calculated using the log-rank test.
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analyses [30]. A larger patient cohort including more events
could be considered in future studies.
In conclusion, fully automated AI-based measurements of
imaging biomarkers on PET/CT reflecting prostate tumour
burden showed prognostically significant results. These
measurements may be a clinically valuable tool in the future
for patient stratification and monitoring of individ-
ual therapy.
The AI tool developed in this project is available upon
reasonable request for research purposes at www.reco-
mia.org.
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